Fisetin-loaded nanocochleates: Formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study

Expert Opinion on Drug Delivery

Volumn 11, Issue 1, 2014, Pages 17-29

  Bothiraja, Chellampillai ^a   Yojana, Bhagwat D ^b   Pawar, Atmaram P ^a   Shaikh, Karimunnisa S ^c   Thorat, Uday H ^b  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b UNIVERSITY OF PUNE   (India)

^c Affiliated to Savitribai Phule Pune University   (India)

Author keywords

Breast cancer cells; Dimyristoylphosphatidylcholine; Fisetin; Haemolysis; Nanocochleates; Pharmacokinetics

Indexed keywords

FISETIN; NANOCHLEATE; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CALCIUM; CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; FLAVONOID;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG SAFETY; ENCAPSULATION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PARTICLE SIZE; PH; TISSUE DISTRIBUTION; ANIMAL; BIOAVAILABILITY; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE; MALE; MCF 7 CELL LINE; MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CALCIUM; CELL SURVIVAL; CELLS, CULTURED; CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG CARRIERS; ERYTHROCYTES; FLAVONOIDS; HEMOLYSIS; HUMANS; MALE; MCF-7 CELLS; MICE; TISSUE DISTRIBUTION;

EID: 84890732954     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.860131     Document Type: Article

References (55)

1. Bothiraja C, Pawar AP. Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. Eur J Drug Metab Pharmacokinet 2011a;35(3-4):123-9
2. Botelho MA, Rao VS, Carvalho CB, et al. Lippia sidoides and Myracrodruon urundeuva gel prevents alveolar bone resorption in experimental periodontitis in rats. J Ethnopharmacol 2007;113(3):471-8
3. Botelho MA, Rao VS, Montenegro D, et al. Effects of a herbal gel containing carvacrol and chalcones on alveolar bone resorption in rats on experimental periodontitis. Phytother Res 2008;22(4):442-9
4. Szliszka E, Helewski KJ, Mizgala E, Krol W. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int J Oncol 2011;39(4):771-9
5. Liu W, Tian R, Hu W, et al. Preparation and evaluation of selfmicroemulsifying drug delivery system of baicalein. Fitoterapia 2012;83(8):1532-9
6. Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: Implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med 2013;65(12):117-30
7. Zhao L, Zhang L, Meng L, et al. Design and evaluation of a self-microemulsifying drug delivery system for apigenin. Drug Dev Ind Pharm 2013;39(5):662-9
8. Tang J, Xu N, Ji H, et al. Eudragit nanoparticles containing genistein: Formulation, development and bioavailability assessment. Int J Nanomed 2011;6:2429-35
9. Puhl AC, Fagundes M, Santos KC, et al. Preparation and characterization of polymeric nanoparticles loaded with the flavonoid luteolin by using factorial design. Int J Drug Deliv 2011;3(4):683-98
10. Tan Q, Liu WD, Guo CY, Zhai GX. Preparation and evaluation of quercetinloaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 2011;6(8):1621-30
11. Arai Y, Watanabe S, Kimira M, et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 2000;130(9):2243-50
12. Inkielewicz-Stepniak I, Radomski MW, Wozniak M. Fisetin prevents fluorideand dexamethasone-induced oxidative damage in osteoblast and hippocampal cells. Food Chem Toxicol 2012;50(3-4):583-9
13. Cho Y, Chung JH, Do HJ, et al. Effect of fisetin supplementation on hepatic lipogenesis and glucose metabolism in Sprague-Dawley rats fed on a high fat diet. Food Chem 2013;139(1-4):720-7
14. Ju YK, Young KJ, Won J, Myeong JN. Fisetin induces apoptosis in Huh-7 cells via downregulation of BIRC8 and Bcl2L2. Food Chem Toxicol 2010;48(8-9):2259-64
15. Raygude KS, Kandhare AD, Ghosh P, Bodhankar SL. Anticonvulsant effect of fisetin by modulation of endogenous biomarkers. Biomed Prevent Nutr 2012;2(3):215-22
16. Touil YS, Seguin J, Scherman D, Chabot GG. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol 2011a;68(2):445-55
17. Tripathi R, Samadder T, Gupta S, et al. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther 2011;10(2):255-68
18. Yu SH, Yang PM, Peng CW, et al. Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis. Cancer Lett 2011;300(1):94-104
19. Adhami VM, Syed DN, Khan N, Mukhtar H. Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 2012;84(10):1277-81
20. Chien CS, Shen KH, Huang JS, et al. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 2010;333(1-2):169-80
21. Khan N, Asim M, Afaq F, et al. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 2008;68(20):8555-63
22. Mignet N, Seguin J, Ramos Romano M, et al. Development of a liposomal formulation of the natural flavonoid fisetin. Int J Pharm 2012;423(1):69-76
23. Touil YS, Auzeil N, Boulinguez F, et al. Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite. Biochem Pharmacol 2011b;82(11):1731-9
24. Seguin J, Brulle J, Boyer R, et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm 2013;444(1-2):146-54
25. Ragelle H, Crauste-Manciet S, Seguin J, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm 2012;427(2):452-9
26. Crauste-Manciet S, Larquet E, Khawand K, et al. Lipidic spherulites: Formulation optimisation by paired optical and cryoelectron microscopy. Eur J Pharm Biopharm 2013; In press
27. Capek I. Degradation of kinetically-stable o/w emulsions. Adv Colloid Interface Sci 2004;107(2-3):125-55
28. Zarif L, Graybill J, Perlin D, Mannino RJ. Cochleates: New lipid based drug delivery system. J Liposome Res 2000;10(4):523-38
29. Zarif L. Elongated supramolecular assemblies in drug delivery. J Control Release 2002;81(1-2):7-23
30. Delmarre D, Lu R, Tatton N, et al. Cochleate-mediated delivery. Drug Deliv Technol 2004;9(4):64-9
31. Zarif L, Perlin D. Amphotericin B nanocochleates: From formulation to oral efficacy. Drug Deliv Technol 2002;2(4):34-7
32. Pham TT, Loiseau PM, Barratt G. Strategies for the design of oral bioavailable antileishmanial treatments. Int J Pharm 2013;454(1):539-52
33. Paleos CM, Tsiourvas D, Sideratou Z. Preparation of multicompartment lipidbased systems based on vesicle interactions. Langmuir 2012;28(5):2337-46
34. Acevedo R, Callico A, Del Camo J, et al. Intranasal administration of peroteoliposome-derived cochleates from Vibrio cholera induced mucosal and systemic immune responses in mice. Methods 2009;49(4):309-15
35. Shaikh K, Pawar A. Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal. Drug Dev Ind Pharm 2012
36. Evans CC, Zasadzinski J. Encapsulating vesicles and colloids from cochleate cylinders. Langumuir 2003;19(8):3109-13
37. Bothiraja C, Pawar AP. Andrographolide, a novel bioactive phytoconstituent encapsulated in sustained release biodegradable nanoparticles. Int J Nanotechnol 2011b;8(8-9):764-78
38. Bothiraja C, Kapare HS, Pawar AP, Shaikh KS. Development of plumbaginloaded phospholipid-Tween- 80 mixed micelles: Formulation, optimization, effect on breast cancer cells and human blood/ serum compatibility testing. Ther Deliv 2013;4(10):1247-59
39. Tong S, Xiang B, Dong D, Qi X. Enhanced antitumor efficacy and decreased toxicity by self-Associated docetaxel in phospholipid-based micelles. Int J Pharm 2012;434(1-2):413-19
40. Shia CH, Tsai SY, Kuo SC, et al. Metabolism and pharmacokinetics of 2,3',4',7-Tetrahydroxyflavone (fisetin), 5-hydroxyflavone and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem 2009;57(1):83-9
41. Gonzaga LW, Botelho MA, Queiroz DB, et al. Nanotechnology in hormone replacement therapy: Safe and efficacy of transdermal estriol and estradiol nanoparticles after 5 years follow-up study. Lat Am J Pharm 2012;31(3):442-50
42. Botelho MA, Martins JG, Ruela RS, et al. Nanotechnology in ligature-induced periodontitis: Protective effect of a doxycycline gel with nanoparticles. J Appl Oral Sci 2010;18(4):335-42
43. Botelho MA, Martins JG, Ruela RS, et al. Protective effect of locally applied carvacrol gel on ligature-induced periodontitis in rats: A tapping mode AFM study. Phytother Res 2009;23(10):1439-48
44. Bennet D, Kim S. A transdermal delivery system to enhance quercetin nanoparticle permeability. J Biomater Sci Polymer Ed 2013;24(2):185-209
45. Touil YS, Fellous A, Scherman D, Chabot GG. Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization. Nutr Cancer 2009;61(3):310-21
46. Marone PA, Elsmore SK, Sandulow J, Mannino RJ. Structural determinants of divalent cation-Induced phosphatidylserine cochleate crystallization. Microsc Microanal 2005;11(2):1244-5
47. Zarif L. Cochleates as nanoparticular drug carriers. In: Torchilin VP, editor. Nanoparticulates as drug carriers. Imperial College Press; London; 2006. p. 349-66
48. Delmarre D, Gould-Fogerite S, Mannino RJ. Formulation of hydrophobic drugs into cochleate delivery vehicles: A simplified protocol & bioral TM formulation kit. Drug Deliv Technol 2004;4(1):1-10
49. Jin T, Zarif L, Raphael M. Nanocochleate formulations process of preparation and method of delivery of pharmaceutical agents. US 6,153,217; 2000
50. Newton C, Pangborn W, Nir S, Papahadjopoulos D. Specificity of Ca++ and Mg++ binding to phosphatidylserine vesicles and resultant phase changes of bilayer membrane structure. Biochem Biophys Acta 1978;506(2):281-7
51. Lichtenberger LM, Graziani LA, Dial EJ, et al. Role of surface-Active phospholipids in gastric cytoprotection. Science 1983;219(4590):1327-9
52. Fahr A, Van HP, Kuntsche J, Leigh ML. Lipophilic drug transfer between liposomal and biological membranes: What does it mean for parenteral and oral drug delivery? J Liposome Res 2006;16(3):281-301
53. Leonhard V, Alasino RV, Bianco ID, et al. Self -Assembled micelles of monosialogangliosides as nanodelivery vehicles for taxanes. J Control Release 2012;162(3):619-27
54. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;47(1):55-64
55. Soma D, Kitayama J, Ishigami H, et al. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res 2009;155(1):142-6